



Lisa Holer

Kontakt

Lisa Holer

Publikationen (3)

Schmid S, Holer L, Gysel K, Koster K, Rothschild S, Boos L, Frehner L, Cardoso Almeida S, Britschgi C, Metaxas Y, Mark M, Froesch P, Janthur W, Allemann A, Waibel C, Von der Mühl-Schill C, Früh M, Mauti L. Real-World Outcomes of Patients With Malignant Pleural Mesothelioma Receiving a Combination of Ipilimumab and Nivolumab as First- or Later-Line Treatment. *JTO Clin Res Rep* 2024; 5:100735.

Colombo I, Koster K, Holer L, Haefliger S, Rabaglio-Poretti M, Bastian S, Schwitter M, Eckhardt K, Hayoz S, Mc Laughlin A, Kloft C, Klose M, Halbherr S, Baumgartner C, Sessa C, Stathis A, Hess D, Jörgler M. TLD-1, a novel liposomal doxorubicin, in patients with advanced solid tumors: Dose escalation and expansion part of a multicenter open-label phase I trial (SAKK 65/16). *Eur J Cancer* 2024; 201:113588.

Addeo A, Rothschild S, Holer L, Schneider M, Waibel C, Haefliger S, Mark M, Fernandez E, Mach N, Mauti L, Jermann P, Alborelli I, Calgua B, Savic-Prince S, Joerger M, Früh M. Fibroblast growth factor receptor (FGFR) inhibitor rogaratinib in patients with advanced pretreated squamous-cell non-small cell lung cancer over-expressing FGFR mRNA: The SAKK 19/18 phase II study. *Lung Cancer* 2022; 172:154-159.

Projekte (0)

Keine Resultate gefunden.

Kantonsspital St.Gallen

Rorschacher Strasse 95

CH-9007 St.Gallen

T: +41 71 494 11 11

support.forschung@kssg.ch